News
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
NanoViricides, Inc. reports filing the Annual Report on Form 10-K with SEC showcasing achievements including Phase II trials for NV-387, an antiviral drug for Mpox and Ebola. Financials and milestones are detailed -
-
-
COMMUNIQUÉ DE PRESSE
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
NanoViricides, Inc. starts enrolling patients in Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebolavirus in DRC. Trial aims for safe dosing protocol and efficacy evaluation for Ebola virus infection -
-
-
COMMUNIQUÉ DE PRESSE
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
NanoViricides, Inc. initiates Phase II Clinical Trial of Novel Antiviral Drug NV-387 for Monkeypox in DRC led by Prof. Vivi Maketa Tevuzula. Trial aims to evaluate safety and efficacy, potential impact on pandemic response -
